BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29745043)

  • 21. Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer.
    Guo X; Li D; Wu Y; Chen Y; Zhou X; Wang X; Huang X; Li X; Yang H; Xing J
    Lung Cancer; 2015 Feb; 87(2):162-8. PubMed ID: 25576295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
    Topkan E; Ozdemir Y; Kucuk A; Besen AA; Mertsoylu H; Sezer A; Selek U
    PLoS One; 2019; 14(7):e0218627. PubMed ID: 31329602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy.
    Kanzaki H; Kataoka M; Nishikawa A; Uwatsu K; Nagasaki K; Nishijima N; Ochi T; Mochizuki T
    Int J Clin Oncol; 2016 Oct; 21(5):853-861. PubMed ID: 27125214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC).
    Rieber J; Deeg A; Ullrich E; Foerster R; Bischof M; Warth A; Schnabel PA; Muley T; Kappes J; Heussel CP; Welzel T; Thomas M; Steins M; Dienemann H; Debus J; Hoffmann H; Rieken S
    Lung Cancer; 2016 Jan; 91():41-7. PubMed ID: 26711933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patients.
    Coscio A; Chang DW; Roth JA; Ye Y; Gu J; Yang P; Wu X
    Carcinogenesis; 2014 Jun; 35(6):1284-91. PubMed ID: 24517998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy.
    Kang MK; Lee SY; Choi JE; Do SK; Cho MJ; Kim JS; Park JY
    Cancer Med; 2021 Nov; 10(22):8071-8078. PubMed ID: 34612596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study.
    Ouyang WW; Su SF; Hu YX; Lu B; Ma Z; Li QS; Li HQ; Geng YC
    BMC Cancer; 2014 Jul; 14():491. PubMed ID: 25001175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
    Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB
    Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.
    Li R; Gu J; Heymach JV; Shu X; Zhao L; Han B; Ye Y; Roth J; Wu X
    Carcinogenesis; 2017 Apr; 38(4):419-424. PubMed ID: 28186269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
    Vasile E; Tibaldi C; Leon GL; D'Incecco A; Giovannetti E
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1189-94. PubMed ID: 25504507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases.
    Chiang Y; Yang JC; Hsu FM; Chen YH; Shih JY; Lin ZZ; Lan KH; Cheng AL; Kuo SH
    PLoS One; 2015; 10(12):e0145936. PubMed ID: 26720170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
    McAvoy S; Ciura K; Wei C; Rineer J; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):819-27. PubMed ID: 25220718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
    Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
    J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
    Topkan E; Parlak C; Selek U
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):697-704. PubMed ID: 24035331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.